Log In
BCIQ
Print this Print this
 

sumatriptan nasal powder (Onzetra Xsail) (formerly AVP-825)

Also known as: Intranasal sumatriptan powder, OptiNose sumatriptan

  Manage Alerts
Collapse Summary General Information
Company OptiNose Inc.
DescriptionLow-dose sumatriptan powder delivered intranasally using OptiNose Bi-Directional Breath Powered intranasal delivery technology
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentApproved
Standard IndicationMigraine
Indication DetailsTreat acute migraine; Treat migraine with or without aura; Treat moderate to severe acute migraine pain
Regulatory Designation U.S. - Standard Review (Treat acute migraine)
PartnerOtsuka Pharmaceutical Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$110.0M

$20.0M

$90.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/15/2013

$110.0M

$20.0M

$90.0M

Get a free BioCentury trial today